Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease

British Journal of Clinical Pharmacology

Volumn 58, Issue 5, 2004, Pages 528-535

  Cheng, Caroline W R ^a   Woo, Kam Sang ^a   Chan, Juliana C N ^a   Tomlinson, Brian ^a   You, Joyce H S ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Chinese patients; LDL reduction; Patient adherence; Statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHINESE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; CORONARY RISK; DOSE TIME EFFECT RELATION; FEMALE; HIGH RISK POPULATION; HONG KONG; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; AGED; ANTILIPEMIC AGENTS; CHINA; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY DISEASE; FEMALE; GUIDELINE ADHERENCE; HONG KONG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; SIMVASTATIN;

EID: 9144273813     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02202.x     Document Type: Article

References (38)

1. Chan WK, Chui A, Ko GTC et al. Ten-year cardiovascular risk in a Hong Kong population. J Cardiovasc Risk 1999; 6: 163-9.
2. Website: Government of Hong Kong, SAR, China. http://www.info.gov.hk/dh/ diseases/index.htm Accessed 3 November 2003.
3. Fu FH. The prevalence of cardiovascular disease risk factors of Hong Kong Chinese. J Sports Med Phys Fitness 2001; 41: 491-9.
4. Lipid Research Clinic Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. (I) Reduction in Incidence of Coronary Heart Disease; (II) the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 351-74.
5. Downs JR, Clearfield M, Weis S et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22.
6. The Long-term intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
7. Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
8. Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
9. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
11. Anonymous. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
12. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J General Intern Med 1999; 14: 711-7.
13. LaRose JH, LaRose JC. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med 2000; 9: 1169-75.
14. Cramer JA, Mattson RH, Prevey ML et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273-7.
15. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000; 3: 417-26.
16. Avorn J, Monette J, Lacour A et al. Persistence of use of lipid-lowering medications. JAMA 1998; 279: 1458-62.
17. Eriksson MHA, Dell K, Holme I et al. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care. J Intern Med 1998; 243: 373-80.
18. Larsen J, Andersen M, Kragstrup J, Lars F. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharm 2002; 53: 375-8.
19. Benner JS, Glynn RJ, Mogun H et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-61.
20. Kiortsis DN, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther 2000; 25: 445-51.
21. Kaneda T. Health, work, and family support in China. Dissertations Abstracts Int, A Humanities Social Sci 2003; 63: 4107-A.
22. Chou KL, Chi I. Social support exchange among elderly Chinese people and their family members in Hong Kong: a longitudinal study. Int J Aging Hum Dev 2001; 53: 329-46.
23. Golin CE, Liu HH, Hays RD et al. A prospective study of predictors of adherence to combination antiretroviral medication. J General Intern Med 2002; 17: 756-65.
24. Leung TN, Haines CJ, Chung TKH. Five-year compliance with hormone replacement therapy in postmenopausal Chinese women in Hong Kong. Maturitas 2001; 39: 195-201.
25. Molassiotis A, Nahas-Lopez V, Chung WYR, Lam SWC, Li CKP, Lau TFJ. Factors associated with adherence to antiretroviral medication in HIV infected patients. Int J STD AIDS 2002; 13: 301-10.
26. Fong OW, Ho CF, Fung LY et al. Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Med 2003; 4: 133-8.
27. Ammassari A, Trotta MP, Murri R et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002; 31 (Suppl. 3): 123-7.
28. Brown J, Fitzpatrick R. Factors influencing compliance with dietary restrictions in dialysis patients. J Psychosom Res 1998; 32: 191-6.
29. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997; 24: 317-35.
30. Rudd P. Compliance with antihypertensive therapy: a shifting paradigm. Cardiol Rev 1994; 2: 230-40.
31. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-7.
32. McLane CG, Zyzanski SJ, Flocke SA. Factors associated with medication noncompliance in rural elderly hypertensive patients. Am J Hypertens 1995; 8: 206-9.
33. Anonymous. Compliance and adverse event withdrawal. Their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997; 18: 1718-24.
34. Tomlinson B, Lan W. Hypothyroidism and simvastatin. HKMJ 2001; 7: 219-20.
35. Itoh T, Matsumoto M, Hougaku H et al. Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. Clin Ther 1997; 19: 487-97.
36. Merck & Co., Inc. Zocor (Simvastatin) Prescribing Information. Whitehouse Station, NJ: Merck, Inc., 2004.
37. Zhou BF, Stamler J, Dennis B et al. Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: the INTERMAP study. J Hum Hypertens 2003; 17: 623-30.
38. Woo J, Leung SS, Ho SC et al. Dietary intake and practice in the Hong Kong Chinese population. J Epidemiol Community Health 1998; 52: 631-7.